Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Zelenskyy victory plan: Replace US troops at outposts in Europe with battle-hardened Ukrainians ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...